CF PharmTech (2652 HK)

Analysis

Health Care • China

CF PharmTech is a specialty pharmaceutical company focused on the research, development, manufacturing, and commercialization of inhalation technologies and respiratory drugs. The company specializes in treatments for asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis, with key products including budesonide suspension for inhalation and azelastine hydrochloride and fluticasone propionate nasal spray. Headquartered in Suzhou, China, the company was founded in 2007.

Refresh

Exchange Announcement • 08 Oct 2026 19:32

Next Day Disclosure Return

Exchange Announcement • 07 Oct 2026 18:35

Next Day Disclosure Return

Exchange Announcement • 06 Oct 2026 18:04

Next Day Disclosure Return

Exchange Announcement • 05 Oct 2026 22:25

Voluntary Announcement Voluntary Extension Of Lock-Up Period For Shares Held By Core Management By Six Months

Exchange Announcement • 05 Oct 2026 19:33

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00